{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-25-000070","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2025-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.627478+00:00","generated_at":"2026-05-24T05:02:51.592430+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Zentalis FY2024 cash $371.1M; azenosertib 34.9% ORR in PROC; cash runway to late 2027","bullets":["Cash $371.1M; projected runway to late 2027. FY2024 op expenses $258.6M, down from $299.5M.","Azenosertib monotherapy 34.9% ORR (n=43) in Cyclin E1+ PROC from DENALI Part 1b; mDOR 6.3 months.","FDA Fast Track for azenosertib in PROC. DENALI Part 2 enrollment H1 2025, topline data by end 2026.","New CEO Julie Eastland, CMO Ingmar Bruns, and other executives appointed in Nov 2024.","Jan 2025 strategic restructuring to reduce costs; workforce reduction substantially complete Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-25-000070","json":"https://secwatch.observer/filing/0001725160-25-000070.json","markdown":"https://secwatch.observer/filing/0001725160-25-000070.md","text":"https://secwatch.observer/filing/0001725160-25-000070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000070/0001725160-25-000070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000070/zntl-20250326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T05:02:51.592430+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}